Adoptive transfer of antigen-specific T cells represents a major advance in cancer
immunotherapy, with robust clinical outcomes in some patients. Both the number of …

Synthetic receptor signalling has the potential to endow adoptively transferred T cells with
new functions that overcome major barriers in the treatment of solid tumours, including the …

Expansion and differentiation of antigen-experienced PD-1+ TCF-1+ stem-like CD8+ T cells
into effector cells is critical for the success of immunotherapies based on PD-1 blockade …

CD8+ T cells can mediate eradication of established tumors, and strategies to amplify tumor-
reactive T-cell numbers by immunization or ex vivo expansion followed by adoptive transfer …

To date, no immunotherapy approaches have managed to fully overcome T-cell exhaustion,
which remains a mandatory fate for chronically activated effector cells and a major …

Successful adoptive T-cell therapy has been demonstrated in viral disease, and selected
forms of cancer. However, it is limited by the difficulty to efficiently isolate and amplify …

The therapeutic potential of recombinant cytokines has been limited by the severe side
effects of systemic administration. We describe a strategy to reduce the dose-limiting …

The immunostimulatory cytokine interleukin-2 (IL-2) is a growth factor for a wide range of
leukocytes, including T cells and natural killer (NK) cells,,. Considerable effort has been …

Cancer immunotherapy based on genetically redirecting T cells has been used successfully
to treat B cell malignancies,–. In this strategy, the T cell genome is modified by integration of …

Mature donor T cells cause graft-versus-host disease (GVHD), but they are also the main
mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow …